University Hospital Erlangen

Kisqali (ribociclib) + endocrine therapy (ET) reduces recurrence risk by 28.5% beyond 3 years in HR+/HER2- early breast cancer, with consistent benefits across subgroups, including node-negative disease. Safety remains consistent with low-grade adverse events. Results to be presented at ESMO; FDA action expected in Q3.

A monocentric clinical study on Pompe disease (PD) was conducted at University Hospital Erlangen (UHE) and University Medical Center Göttingen (UMG), involving 18+ PD patients and healthy volunteers (HV) matched by age and sex. The study included clinical assessments, ultrasound, MSOT, and MRI imaging. MSOT imaging used a hybrid system capable of acquiring interleaved US images for coregistration, with data analyzed using viewMSOT software. The study aimed to compare PD patients with HV through various imaging techniques and clinical assessments, including lung function tests and muscle strength evaluations.